RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Editas Medicine ROA 2024

Editas Medicine ROA

-0.31

Editas Medicine Dividend yield

Ticker

EDIT

ISIN

US28106W1036

WKN

A2AC4K

In 2024, Editas Medicine's return on assets (ROA) was -0.31, a -28.38% increase from the -0.43 ROA in the previous year.

Editas Medicine Aktienanalyse

What does Editas Medicine do?

Editas Medicine Inc. is a rising biopharmaceutical company specializing in the development of groundbreaking therapies based on genome editing. Its goal is to combat genetic diseases and other genetically related disorders by selectively modifying DNA sequences. The company was founded in 2013 by a group of renowned scientists, including prominent genome editors Jennifer Doudna and George Church. Over the years, Editas Medicine Inc. has established itself as a pioneer in the field of genome editing and has received numerous awards and funding. Its business model revolves around researching and developing innovative therapies based on genetic modifications, using approaches such as CRISPR/Cas9, TALEN, and zinc finger nucleases. The company aims to develop treatments for previously incurable, severe diseases. Its activities are divided into various business areas, including the exploration of gene therapies, the development of medications based on CRISPR/Cas9 technology, and the research of genome-based diagnostic options. Editas Medicine Inc. has already introduced some products to the market or is in advanced stages of development, such as the medication LCA10 for a rare form of blindness and the medication CEP290 for a severe genetic disease. Overall, Editas Medicine Inc. has experienced remarkable growth in recent years, becoming one of the key players in genome editing. The market for gene therapies and genome-based treatments has significant growth potential, making the company's prospects promising. Editas Medicine Inc. is dedicated to advancing genomic medicine by developing groundbreaking solutions for incurable diseases and providing a platform for new technologies in the market. Editas Medicine ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Editas Medicine's Return on Assets (ROA)

Editas Medicine's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Editas Medicine's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Editas Medicine's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Editas Medicine’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Editas Medicine Stock

What is the Return on Assets (ROA) of Editas Medicine this year?

The Return on Assets (ROA) of Editas Medicine is -0.31 undefined this year.

What was the ROA of Editas Medicine compared to the previous year?

The ROA of Editas Medicine has increased by -28.38% compared to the previous year.

What consequences do high ROA have for investors of Editas Medicine?

A high ROA is advantageous for investors of Editas Medicine, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Editas Medicine?

A low ROA can be unfavorable for investors of Editas Medicine as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Editas Medicine affect the company?

An increase in ROA of Editas Medicine can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Editas Medicine impact the company?

A reduction in the ROA of Editas Medicine can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Editas Medicine?

Some factors that can influence the ROA of Editas Medicine include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Editas Medicine important for investors?

The ROA of Editas Medicine is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Editas Medicine take to improve ROA?

To improve ROA, Editas Medicine can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Editas Medicine pay?

Over the past 12 months, Editas Medicine paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Editas Medicine is expected to pay a dividend of 0 USD.

What is the dividend yield of Editas Medicine?

The current dividend yield of Editas Medicine is .

When does Editas Medicine pay dividends?

Editas Medicine pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Editas Medicine?

Editas Medicine paid dividends every year for the past 0 years.

What is the dividend of Editas Medicine?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Editas Medicine located?

Editas Medicine is assigned to the 'Health' sector.

Wann musste ich die Aktien von Editas Medicine kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Editas Medicine from 5/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/1/2024.

When did Editas Medicine pay the last dividend?

The last dividend was paid out on 5/1/2024.

What was the dividend of Editas Medicine in the year 2023?

In the year 2023, Editas Medicine distributed 0 USD as dividends.

In which currency does Editas Medicine pay out the dividend?

The dividends of Editas Medicine are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Editas Medicine stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Editas Medicine

Our stock analysis for Editas Medicine Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Editas Medicine Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.